Modex Therapeutics Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
Viruses of the Betacoronavirus genus that bind to angiotensin-converting enzyme 2 (ACE2) are the coronaviruses posing the most significant pandemic risk. Sarbecoviruses of this genus caused the severe acute respiratory syndrome (SARS) epidemic and the SARS-CoV-2 pandemic. Therefore, new vaccines with broader protection from ACE2-binding sarbecoviruses and emerging variants of concern are urgently needed.
TANK-binding kinase 1 (TBK1) serves prominent innate immune functions via complex interactions with adaptor proteins to affect phosphorylation of NF-κB (NF-κB). TBK1 is at the nexus of multiple pathways connecting interferon pathway activation and this is ultimately beneficial or hyperinflammatory-pathological in the context of viral infections.
Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers at Ningbo Combireg Pharmaceutical Technology Co. Ltd. and Versitech Ltd. have described benzothiazole compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Novel effective antivirals against SARS-CoV-2 are needed because of the emergence of novel variants and the potential risk of SARS-CoV-2/MERS-CoV recombination. The SARS-CoV-2 main protease (Mpro) is a promising antiviral target. Mpro presents a His41-Cys145 catalytic dyad in the central part of its active site, which confers a natural advantage for developing covalent drugs.
Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).
Wistar Institute of Anatomy & Biology has synthesized new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19).
Viral proteases are well-established therapeutic targets in HIV and hepatitis C virus infections. Following the recent COVID-19 pandemic, one of the strategies in place is SARS-CoV-2 main protease (Mpro) inhibition, given the crucial role of SARS-CoV-2 Mpro in the replication of the virus.
RSS
